Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1955 1
1957 1
1976 1
1978 1
1979 1
1980 2
1981 1
1983 4
1984 2
1985 2
1986 4
1987 1
1988 2
1989 1
1990 9
1991 2
1992 4
1993 2
1994 4
1995 3
1996 7
1997 3
1998 5
1999 15
2000 35
2001 48
2002 84
2003 89
2004 111
2005 121
2006 141
2007 122
2008 145
2009 177
2010 196
2011 231
2012 241
2013 254
2014 296
2015 286
2016 260
2017 284
2018 285
2019 196
2020 19
Text availability
Article attribute
Article type
Publication date

Search Results

3,314 results
Results by year
Filters applied: . Clear all
Page 1
Glucocorticoid receptor modulators.
Meijer OC, Koorneef LL, Kroon J. Meijer OC, et al. Ann Endocrinol (Paris). 2018 Jun;79(3):107-111. doi: 10.1016/j.ando.2018.03.004. Epub 2018 May 3. Ann Endocrinol (Paris). 2018. PMID: 29731108 Review.
Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues.
Graves PR, Aponte-Collazo LJ, Fennell EMJ, Graves AC, Hale AE, Dicheva N, Herring LE, Gilbert TSK, East MP, McDonald IM, Lockett MR, Ashamalla H, Moorman NJ, Karanewsky DS, Iwanowicz EJ, Holmuhamedov E, Graves LM. Graves PR, et al. ACS Chem Biol. 2019 May 17;14(5):1020-1029. doi: 10.1021/acschembio.9b00222. Epub 2019 May 1. ACS Chem Biol. 2019. PMID: 31021596 Free PMC article.
Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.
Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M. Ishizawa J, et al. Cancer Cell. 2019 May 13;35(5):721-737.e9. doi: 10.1016/j.ccell.2019.03.014. Epub 2019 May 2. Cancer Cell. 2019. PMID: 31056398 Free PMC article.
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Gallant J, et al. Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31. Lancet. 2017. PMID: 28867497 Clinical Trial.
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine.
Wohl D, Clarke A, Maggiolo F, Garner W, Laouri M, Martin H, Quirk E. Wohl D, et al. Patient. 2018 Oct;11(5):561-573. doi: 10.1007/s40271-018-0322-8. Patient. 2018. PMID: 29956087 Free PMC article. Clinical Trial.
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, Hansen TM, Risi RM, Frey R, Manaves V, Shaw B, Algire M, Hessler P, Lam LT, Uziel T, Faivre E, Ferguson D, Buchanan FG, Martin RL, Torrent M, Chiang GG, Karukurichi K, Langston JW, Weinert BT, Choudhary C, de Vries P, Van Drie JH, McElligott D, Kesicki E, Marmorstein R, Sun C, Cole PA, Rosenberg SH, Michaelides MR, Lai A, Bromberg KD. Lasko LM, et al. Nature. 2017 Oct 5;550(7674):128-132. doi: 10.1038/nature24028. Epub 2017 Sep 27. Nature. 2017. PMID: 28953875 Free PMC article.
Structural basis of small-molecule inhibition of human multidrug transporter ABCG2.
Jackson SM, Manolaridis I, Kowal J, Zechner M, Taylor NMI, Bause M, Bauer S, Bartholomaeus R, Bernhardt G, Koenig B, Buschauer A, Stahlberg H, Altmann KH, Locher KP. Jackson SM, et al. Nat Struct Mol Biol. 2018 Apr;25(4):333-340. doi: 10.1038/s41594-018-0049-1. Epub 2018 Apr 2. Nat Struct Mol Biol. 2018. PMID: 29610494
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.
Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, Rockstroh JK, Molina JM, Koenig E, Liu YP, Custodio J, Andreatta K, Graham H, Cheng A, Martin H, Quirk E. Daar ES, et al. Lancet HIV. 2018 Jul;5(7):e347-e356. doi: 10.1016/S2352-3018(18)30091-2. Epub 2018 Jun 18. Lancet HIV. 2018. PMID: 29925490 Clinical Trial.
Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.
Woolley AE, Singh SK, Goldberg HJ, Mallidi HR, Givertz MM, Mehra MR, Coppolino A, Kusztos AE, Johnson ME, Chen K, Haddad EA, Fanikos J, Harrington DP, Camp PC, Baden LR; DONATE HCV Trial Team. Woolley AE, et al. N Engl J Med. 2019 Apr 25;380(17):1606-1617. doi: 10.1056/NEJMoa1812406. Epub 2019 Apr 3. N Engl J Med. 2019. PMID: 30946553 Clinical Trial.
3,314 results
Jump to page
Feedback